TenNor Therapeutics team attended ASM Microbe 2016 Conference held in Boston USA and presented TNP-2092 for Helicobacter pylori infection (HPI) program in public the first time.

TenNor submitted a series of 7 poster abstracts around dual-acting molecule TNP-2092 for HPI program and all were accepted for presentation at the conference. TenNor was also selected by the ASM Program Committee to present TNP-2092 program in a “New Antimicrobial Agents” session. On behalf of TenNor Therapeutics, Dr. Zhenkun Ma, Founder and CEO, provided an overview of the TNP-2092 HPI program to a general audience.

TenNor’s collaborators William Weiss, Mark Pulse (both from UNT Health Science Center) and Gregory Robertson (Colorado State University), together with TenNor’s team members Xiaomei Wang and Xiangyi Xu participated in the poster presentations.

Link to TenNor posters：

Annex:

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com